Skip to content
10-Q

Quarterly Report

Bristol-Myers Squibb Company BMY CELG-RI

0000014272-25-000091

← back to feed
Filed
Apr 24, 2025 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2025 · Apr 17, 2025 2.04B sh
Long Term Debt Q1 2025 · Mar 31, 2025 $46.16B
Long Term Debt Q1 2025 · Dec 31, 2024 $47.6B
Short Term Debt Q1 2025 · Mar 31, 2025 $3.55B
Short Term Debt Q1 2025 · Dec 31, 2024 $2.05B
Cash And Equivalents Q1 2025 · Mar 31, 2025 $10.88B
Cash And Equivalents Q1 2025 · Dec 31, 2024 $10.35B
Stockholders Equity Q1 2025 · Mar 31, 2025 $17.39B
Stockholders Equity Q1 2025 · Dec 31, 2024 $16.34B
Current Liabilities Q1 2025 · Mar 31, 2025 $24.07B
Current Liabilities Q1 2025 · Dec 31, 2024 $23.77B
Total Liabilities Q1 2025 · Mar 31, 2025 $74.98B
Total Liabilities Q1 2025 · Dec 31, 2024 $76.22B
Current Assets Q1 2025 · Mar 31, 2025 $30.78B
Current Assets Q1 2025 · Dec 31, 2024 $29.78B
Total Assets Q1 2025 · Mar 31, 2025 $92.43B
Total Assets Q1 2025 · Dec 31, 2024 $92.6B
Shares Diluted Q1 2025 · Mar 31, 2024 2.02B sh
Dividends Paid Q1 2025 · Mar 31, 2024 $1.21B
Capex Q1 2025 · Mar 31, 2024 $284M
Operating Cash Flow Q1 2025 · Mar 31, 2024 $2.83B
Eps Diluted Q1 2025 · Mar 31, 2024 −$5.89
Eps Basic Q1 2025 · Mar 31, 2024 −$5.89
Sga Expense Q1 2025 · Mar 31, 2024 $2.37B
Rd Expense Q1 2025 · Mar 31, 2024 $2.7B
Net Income Q1 2025 · Mar 31, 2024 −$11.91B
Cost Of Revenue Q1 2025 · Mar 31, 2024 $2.93B
Revenue Q1 2025 · Mar 31, 2024 $11.87B